The broader 2026 context matters: as of May 2026, the FDA has proposed regulatory changes affecting compounded semaglutide and tirzepatide, with a public comment period closing June 29, 2026
The Adipofilling suspension of living adipose and stromal cells can be injected into the dermis, in which case it has no volumetric effect, but exerts a potent regenerative action
Low to moderate levels of ROS contribute to sustaining cellular proliferation and can be a trigger for the activation of the stress-responsive survival pathway, including the glucose transporter 3,4
This suggests a potential shift from testosterone replacement in males with obesity and low testosterone, instead treating excess weight and metabolic health, which can restore hormone levels and preserve fertility
So far, researchers are excited about their potential to curb addiction and improve brain health